Comment on: Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.

Huemer F, Weiss L, Regitnig P, Winder T, Schmitt CA, Thaler J, Wöll E, Greil R.

ESMO Open. 2024 Mar 19;9(4):102973. doi: 10.1016/j.esmoop.2024.102973. Online ahead of print. PMID: 38507896.